Sugi Predict

Sugi Predict / Compounds / SCHEMBL3322351

SCHEMBL3322351

SCHEMBL3322351

Fc1ccc[c]c1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.41
▸ KDM1A O60341 8/20 0.40
▸ MAOA P21397 2/20 0.40
▸ MAOB P27338 2/20 0.40
▸ SLC6A2 P23975 3/20 0.39
▸ SLC6A3 Q01959 3/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HTR1A P08908 2/20 0.38
▸ SLC6A4 P31645 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ CASP3 P42574 1/20 0.38
▸ TAAR1 Q96RJ0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3321449 0.83 MAOB (0.49) MAOAMAOBLMNAPTGS1PTGS2
SCHEMBL11426865 0.82 APP (0.46) NPC1MAOBRAB9ASMN1; SMN2L3MBTL1
SCHEMBL697658 0.82 MAOB (0.46) MAOAMAOBTAAR1
SCHEMBL1190605 0.80 MAPT (0.52) SLC6A2SLC6A3TSHRHTR1ASLC6A4
SCHEMBL2721267 0.79 HPGD (0.41) NPC1MAOAMAOBSLC6A2SLC6A3
SCHEMBL7294363 0.79 L3MBTL1 (0.46) NPC1MAOAMAOBSLC6A2SLC6A3
SCHEMBL11567092 0.79 LMNA (0.47) MAOAMAOBSLC6A2SLC6A3LMNA
SCHEMBL3324331 0.78 RXRA (0.44) MAOAMAOBSLC6A2SLC6A3LMNA
SCHEMBL7466776 0.77 GSTP1 (0.42) MAOAMAOBSLC6A2SLC6A3LMNA
SCHEMBL3767201 0.76 HTR1A (0.49) MAOBHTR1AMAPTL3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058519-A1 QUINAZOLINE DITOSYLATE SALT COMPOUNDS LEO OSPREY LIMITED (GB) 2008-03-06 — — US claimed
EP-1460072-B1 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors GLAXO GROUP LTD (GB) 2006-04-05 — — EP claimed
EP-1460072-A1 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors GLAXO GROUP LIMITED (GB) 2004-09-22 — — EP claimed
EP-1454907-A1 Quninazoline and pyridopyrmidine derivatives Glaxo Group Limited (GB) 2004-09-08 — — EP claimed
CN-1134438-C Bicyclic heteroaromatic compounds, preparation method and use thereof �ձ���ҩ��ʽ���� 2004-01-14 — — CN claimed
WO-1999035132-A1 HETEROCYCLIC COMPOUNDS GLAXO GROUP LIMITED (GB) 1999-07-15 — — WO claimed
WO-2021006267-A1 SALT OF PYRAZOLE DERIVATIVE AND PREPARATION OF PYRAZOLE DERIVATIVE グリーン・テック株式会社 2021-01-14 — — WO disclosed
WO-2020235582-A1 PREVENTIVE AND/OR THERAPEUTIC AGENT FOR MOTOR NEURON DISEASE グリーン・テック株式会社 (JP) 2020-11-26 — — WO disclosed
EP-3323816-A1 NOVEL PYRAZOLE DERIVATIVE Green Tech Co., Ltd. (JP) 2018-05-23 — — EP disclosed
US-20160339027-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2016-11-24 — — US disclosed
US-9399635-B2 Pyrazole derivative GREEN TECH CO., LTD. (JP) 2016-07-26 — — US disclosed
US-20160051551-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-25 — — US disclosed
US-9199973-B2 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors NOVARTIS AG (CH) 2015-12-01 — — US disclosed
EP-1294715-A1 QUINAZOLINE DITOSYLATE SALT COMPOUNDS GLAXO GROUP LIMITED (GB) 2003-03-26 — — EP disclosed
US-20020147205-A1 Heterocyclic compounds NOVARTIS AG (CH) 2002-10-10 — — US disclosed
WO-2002002552-A1 QUINAZOLINE DITOSYLATE SALT COMPOUNDS GLAXO GROUP LIMITED (GB) 2002-01-10 — — WO disclosed
EP-1047694-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-11-02 — — EP disclosed
WO-1999035132-A1 HETEROCYCLIC COMPOUNDS GLAXO GROUP LIMITED (GB) 1999-07-15 — — WO disclosed
WO-1999035146-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-07-15 — — WO disclosed
CN-1151399-A Novel hydroxylpyridinones CIBA GEIGY AG (CH) 1997-06-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058519-A1 QUINAZOLINE DITOSYLATE SALT COMPOUNDS ERBB4, ABL1, ERBB2 NPC1 4015/4885KDM1A 4205/4885MAOA 3669/4885
US-20020147205-A1 Heterocyclic compounds ERBB2, ERBB3, ERBB4 NPC1 2498/4885KDM1A 4409/4885MAOA 887/4885
US-20160339027-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ABL1, ERBB2, SRC NPC1 1696/4885KDM1A 2371/4885MAOA 759/4885
US-20160051551-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ABL1, ERBB2, SRC NPC1 1696/4885KDM1A 2371/4885MAOA 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.